Global Oncology Clinical Trials Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2029
“Global Oncology Clinical Trials Market” is the title of an upcoming report offered by MarketResearch.Biz. The report contains information and data, and inputs from both primary and secondary data sources, that have been verified and validated by experts in the target market. The report presents a thorough study of revenues, historical data, and information, key developments, and strategies by major players that offer vital insights and perspectives in to various scenarios market. Besides critical data and related information, the report includes key trends (both present and future), factors that are driving market growth, factors that are or could be potential restraints to market growth, as well as opportunities that can be leveraged for potential revenue generation in untapped regions and countries. It also covers threats or challenges for existing as well as new entrants in the market. The global oncology clinical trials market has been segmented on the basis of phase, study design, cancer type, as well as regions and countries.
A clinical trial is a research study to find out if a new treatment provides better outcomes than the existing standard of care – the best known available treatment. Clinical trials establish the effectiveness and safety of new cancer treatments.
The increasing number of cancer cases being reported across the world is a primary factor that is expected to continue to fuel the revenue growth of the global oncology clinical trials market over the next 10 years.
Moreover, the growing demand for personalized medication from individuals suffering from various forms of cancer, is a factor that is also slated to contribute to the future market growth of this global industry.
In light of the recent COVID-19 outbreak, the operations of numerous industries have been either temporarily halted or are functioning with a minimal workforce due to enforced lockdowns and imposed restrictions by respective governing bodies. The global oncology clinical trials industry is no different, and this factor is expected to negatively impact market growth in the years to come.
Nonetheless, the drastic increase in investments by key industry players towards robust R&D activities concerned with the development of technologically advanced treatment techniques is another major factor that is anticipated to further augment revenue growth of the global oncology clinical trials market in the foreseeable future.
Segmentation of the global oncology clinical trials market is as follows:
In terms of phase, the phase II segment accounted for the maximum number of revenue shares of the global oncology clinical trials market in 2020, and is expected to continue to do so over the next decade. This can be attributed to the increasing number of studies that are presently in the ‘phase II’ stage.
On the basis of cancer type, the leukemia segment accounted for the highest number of revenue shares of the global oncology clinical trials market in 2020, and is slated to index a high CAGR over the next 10 years. This can be attributed to the steady increase in the incidence of leukemia being reported across the world – it is the most common type of cancer among children, accounting for about 30% of all reported cases.
With respect to study design, the interventional design segment accounted for the highest number of revenue shares of the global oncology clinical trials market in 2020, due to the fact that it is one of the most prominent methods available. The expanded access segment is also anticipated to index significant rate of revenue growth over the next 10 years.
Regional Segmentation and Analysis:
North America accounted for the highest number of revenue shares of the global oncology clinical trials market in 2020, and is slated to index a considerable rate of revenue growth over the forecast period. This can be attributed to the increasing adoption of new technologies in clinical research, rising R&D efforts, as well as favorable support being offered by the governments in this region. The markets in Europe accounted for the second-most number of revenue shares of this global market in 2020. However, the markets in the Asia Pacific region are also expected to register the fastest CAGR in the coming years owing to factors such as, the presence of a large patient pool, as well as improving medical infrastructures in this region.
Segmentation of the Global Oncology Clinical Trials Market:
Segmentation by Phase:
- Phase I
- Phase II
- Phase III
- Phase IV
Segmentation by Study Design:
- Expanded Access
Segmentation by Cancer Type:
- Lung cancer
- Breast cancer
- Thyroid cancer
- Liver cancer
- Skin cancer
- Pancreatic cancer
- Prostate cancer
- Colon & rectal cancer
- Urinary system cancer
- Other cancer
Segmentation by Regions:
- North America
- South America
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2020 Estimated Year 2021 Forecast Period 2021–2030 Revenue in US$
- PAREXEL International Corporation
- PRA Health Sciences
- Syneos Health
- Medpace Holdings Inc.
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!